IHFB Cognacq Jay

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer7 trials
• Prostate cancer2 trials
• Triple-negative breast cancer2 trials
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial

Phase

• Phase 39 trials
• Phase 23 trials
• Phase 1/21 trial

Status

• Recruiting6 trials
• Active, not recruiting3 trials
• Suspended2 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Federation Francophone de Cancerologie Digestive2 trials
• UNICANCER2 trials
• Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD1 trial
• Aragon Pharmaceuticals, Inc.1 trial
• Assistance Publique - Hôpitaux de Paris1 trial
• and 6 more

Running trials

• Recruiting

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· Phase 3· Unicancer· Source

• Recruiting

  Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

  NCT07333066· Phase 3· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source

• Not yet recruiting

  Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

  NCT07150403· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

  NCT06606730· Phase 3· UNICANCER· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

  2023-505660-11-00· Phase 3· Transthera Sciences (Nanjing) Inc.· Source

• Active, not recruiting

  Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine

  NCT05201352· Phase 1/2· Centre Georges Francois Leclerc· Source

• Recruiting

  Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer

  NCT03875781· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

  NCT03079011· Phase 3· UNICANCER· Source

• Active, not recruiting

  An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

  NCT02531516· Phase 3· Aragon Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Triple-negative breast cancer2 recruiting
• Liver and biliary tract cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer

  NCT05328908· Phase 3· Bristol Myers Squibb International Corporation· Source